Looking beyond current treatments for Central Nervous System (CNS) diseases and disorders with high unmet need

VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for CNS diseases and disorders for which current treatments fall short of patient needs, including depression and social anxiety disorder.

Our CNS pipeline is focused on drug candidates with potential for convenient, at-home use, rapid-onset therapeutic benefits, and exceptional safety.

Our CNS Pipeline

Going Beyond Current Treatment Options for Depression and Social Anxiety Disorder

Learn more about our CNS Pipeline

Experienced Leadership

Our experienced leadership team has a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.

Meet Our Team

Stock Information

View Detailed Stock Info
Nasdaq: VTGN Symbol
Day Range
52 Week Range

Email Updates

Be the first to receive news, events & updates Sign Up